Drug Development Drug Pricing Vaccines 
STAT
JUNE 24, 2025
Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association. Sign up to get our biotech newsletter in your inbox.
STAT
FEBRUARY 9, 2024
Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs. Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a listen. Read the rest…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 17, 2024
Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more. Sign up to get our biotech newsletter in your inbox. Read the rest…
STAT
OCTOBER 5, 2023
Damian here with a rare look at a biotech in collapse, Moderna’s ambitious future in vaccines, and what looks like a massive missed opportunity. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, all. Read the rest…
STAT
FEBRUARY 14, 2024
We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. Read the rest…
STAT
MARCH 3, 2025
Also, lots of updates on vaccines, and Ginkgo starts subleasing its lab space. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we bid adieu to NIH luminary Francis Collins. Read the rest…
PharmaVoice
JUNE 16, 2025
Known as the negotiators between health plans, pharmacies and drug companies, pharmacy benefit managers are currently entangled in a national conversation about reform. The pharma industry has long blamed PBMs for rising drug prices, pointing to opaque rebate and profit structures , and proposed policy shifts could take them to task.
Expert insights. Personalized for you.
253 
Let's personalize your content